Pentosan Polysulfate—A “Better Heparin” as Potential Medication for the Treatment of SARS-CoV-2 Infections?

Pentosan Polysulfate Inhibits Attachment and Infection by SARS-CoV-2 In Vitro: Insights into Structural Requirements for Binding

Publication History

Received: 29 March 2022

Accepted: 29 March 2022

Accepted Manuscript online:
01 April 2022

Article published online:
17 May 2022

• References

• 1 Mycroft-West CJ, Su D, Pagani I. et al. Heparin inhibits cellular invasion by SARS-CoV-2: structural dependence of the interaction of the spike S1 receptor-binding domain with heparin. Thromb Haemost 2020; 120 (12) 1700-1715
• 2 van Haren FMP, Page C, Laffey JG. et al. Nebulised heparin as a treatment for COVID-19: scientific rationale and a call for randomised evidence. Crit Care 2020; 24 (01) 454
• 3 Bertini S, Alekseeva A, Elli S. et al. Pentosan polysulfate inhibits attachment and infection by SARS-CoV-2 in vitro: insights into structural requirements for binding. Thromb Haemost 2022;122(06):
• 4 Zhang F, He P, Rodrigues AL. et al. Potential anti-SARS-CoV-2 activity of pentosan polysulfate and mucopolysaccharide polysulfate. Pharmaceuticals (Basel) 2022; 15 (02) 258